Trial Profile
A 2-year Observational Study to Evaluate Safety of Seretide 50/500μg Twice Daily Administered by DISKUS, in Patients With COPD
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Aug 2023
Price :
$35
*
At a glance
- Drugs Salmeterol/fluticasone propionate (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 17 Jan 2014 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov record.
- 16 May 2008 New trial record.